Crescita TherapeuticsTSX:CTX 20 EV-to-FCF is 5.89 as of Jul. 12, 2026, which is 707% above its 10-year median of 0.73. GuruFocus rates TSX:CTX with a GF Score™ of 20/100 and a GF Value™ of C$0.68 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 562 Drug Manufacturers companies, Crescita Therapeutics ranks better than 88.43% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Crescita Therapeutics's Enterprise Value is C$8.50 Mil.
Crescita Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was C$1.44 Mil. Therefore, Crescita Therapeutics's EV-to-FCF for today is 5.89.
The historical rank and industry rank for Crescita Therapeutics's EV-to-FCF or its related term are showing as below:
TSX:CTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.73 Med: 0.73 Max: 39.67
Current: 5.89
During the past 12 years, the highest EV-to-FCF of Crescita Therapeutics was 39.67. The lowest was -13.73. And the median was 0.73.
TSX:CTX's EV-to-FCF is ranked better than 88.43% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.955
vs TSX:CTX: 5.89
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Crescita Therapeutics's PE Ratio (TTM) for today is calculated as:
Crescita Therapeutics's share price for today is C$0.79.
Crescita Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's EV-to-FCF falls into.
Crescita Therapeutics's current Enterprise Value is C$8.50 Mil.
Crescita Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescita Therapeutics (TSX:CTX) has a EV-to-FCF of 5.89 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Crescita Therapeutics and its competitors. This is 707% above median its historical median of 0.73. According to the industry distribution chart, Crescita Therapeutics ranks #65 out of 562 companies in the Drug Manufacturers industry, placing it in the top 11.6%.
Is Crescita Therapeutics' EV-to-FCF too high?
Crescita Therapeutics' current EV-to-FCF of 5.89 is 707% above median its 10-year median of 0.73. The Drug Manufacturers industry median EV-to-FCF is 20.96. Crescita Therapeutics' value of 5.89 is 71.9% below this industry median. Based on the distribution chart, Crescita Therapeutics ranks #65 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Crescita Therapeutics ranks #65 out of 562 companies for EV-to-FCF. This places Crescita Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.96. Crescita Therapeutics' value of 5.89 is 71.9% below this benchmark. While the company's 10-year median is 0.73 vs. the industry median of 20.96, Crescita Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescita Therapeutics's current EV-to-FCF of 5.89 is 71.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Crescita Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescita Therapeutics's current EV-to-FCF is 5.89, which is 707% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current EV-to-FCF is 5.89, which is 707% above median its 10-year median of 0.73 and 71.9% below the Drug Manufacturers industry median of 20.96. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current EV-to-FCF is 5.89 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued.
The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68.
GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.
Key valuation signals for TSX:CTX:
EV-to-FCF: 5.89 (707% above median its 10-year median of 0.73)
GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
Industry Position: 71.9% below the Drug Manufacturers median (#65 of 562)
No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
